The Asia-Pacific region, with over half of the global population, is becoming a growing popular spot for conducting clinical trials by offering lower trial costs, access to large patient pools, and a friendly regulatory environment. These distinguishing traits are increasing interest in medical device, pharmaceutical, and healthcare companies to shift their clinical trial locations to […]
Read More →Asia-Pacific is a top destination for growing healthcare companies, with the APAC Healthcare Analytics Market size projected to increase by USD 20.84 billion at a CAGR of 27.94% between 2023 and 2028. The region offers opportunities for several healthcare products, such as pharmaceuticals, medical devices, cosmetics, and nutraceuticals. As APAC continues to experience economic development […]
Read More →Importing Ancillaries and IMPs for clinical trials in the Asia-Pacific region presents numerous challenges. Navigating diverse regulatory landscapes, and logistical complexities, ensuring quality control, and managing timeliness and costs are critical hurdles. Effective risk mitigation strategies are essential for overcoming potential disruptions. Overall, addressing these challenges is vital for the successful execution of clinical trials […]
Read More →The Asia-Pacific region emerges as a pivotal player in the landscape of clinical trials. They offer unique advantages for conducting impactful research due to diverse populations, varied healthcare infrastructures, and a rich pool of treatment-naive patients. Over the past decade, there has been a notable shift in the global Phase I clinical trials scenario, with […]
Read More →Pharma out-licensing is a strategic approach where a pharmaceutical company licenses its assets, such as drugs or technologies, to external partners. The process and key steps of out-licensing are crucial for companies looking to expand their reach, enhance their product portfolios, and capitalize within the industry. This guide streamlines the out-licensing process, regardless of experience […]
Read More →In the dynamic landscape of the pharma industry, navigating the in-licensing process is a strategic imperative for companies seeking to strengthen their products. This complex journey involves identifying promising assets, negotiating agreements, and ultimately integrating external innovations. In-licensing refers to a formal collaboration where one company provides financial support to another to develop and launch […]
Read More →In the fast-changing global business landscape of today, companies are increasingly seeking expansion into the promising Asia Pacific markets. As organizations target this dynamic region, it becomes essential to recognize and navigate the distinct challenges that can emerge along the way. In this article, we delve into the multifaceted landscape of business expansion in the […]
Read More →The clinical research landscape is shifting drastically due to an increase in the availability of electronic data allowing researchers to make assessments based on available real-world evidence (RWE) obtained from the analysis of real-world data (RWD). Global regulators are encouraging researchers/drug developers utilize the RWE for submissions. Many regulators are accepting the Real-world evidence (RWE) […]
Read More →Covid 19 has caused severe disruptions for many people. According to WHO, as of 31 December 2020, COVID-19 had infected over 82 million people and killed more than 1.8 million worldwide. This pandemic raised the interest of many researchers to find the drug and treatment plans for COVID-19. So, now it’s interesting to know the […]
Read More →The development of new drugs is becoming more expensive and needs infrastructure and efficient resources so, licensing collaborations are becoming a favorable option for many global pharmaceutical companies. These licensing options help companies offset to research and development investments and bypass the cumbersome innovation and development process. As per the global data, in the pharmaceutical […]
Read More →